Australian M&A and equity raisings
2,041 deals since January 2025, with sources and adviser credits where available · as at 20 Nov 2026 · Venture rounds
4 deals · A$32.8mdisclosed · Biotech · Clear
Columns
| Date | Target | Vendor | Acquirer | Type | Status | Value A$m | Sector | Advisers |
|---|---|---|---|---|---|---|---|---|
| Mar 2026 | Imugene | – | – | Placement | Completed | 20.0 | Biotech+1 | McCullough Robertson (issuer)E&P Capital (lead manager)Barrenjoey (lead manager)Bell Potter (lead manager) |
| Jan 2026 | AdAlta | – | – | Placement | Completed | 1.2 | Biotech+1 | Sixty Two Capital (lead manager) |
| Sep 2025 | Neurizon Therapeutics | – | – | Placement | Completed | 5.0 | Biotech+1 | Petra Capital (lead manager) |
| May 2025 | Chimeric Therapeutics | – | – | Placement | Announced | 6.6 | Biotech+2 | PAC Partners (lead manager)Taylor Collison (lead manager) |
Deals come from ASX announcements, scheme booklets, prospectuses, the advisers' own deal announcements and the press. How the data is built